Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04116658 · ClinicalTrials.gov registry record · Phase 1

First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma

A Phase 1 study, sponsored by Enterome.

Completed
Registry status
Phase 1
Development phase
100
Enrollment target

NCT04116658: Completed Phase 1 study, sponsored by Enterome.

NCT04116658 is a Phase 1 study that has completed, run by Enterome. The registered enrollment target is 100 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04116658, a Phase 1 study, has completed, sponsored by Enterome.

COMPLETED
Registry status
Phase 1
Development phase
100 participants
Enrollment target

Study Summary

The purpose of this study is to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in patients with unequivocal evidence of progressive or first recurrent glioblastoma.

Primary Outcome

Incidences of treatment-emergent Serious Adverse Events ( SAEs) using the National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0.

Interventions

  • BIOLOGICAL Multiple dose of EO2401

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2020-07-13
Est. Completion 2024-03-04
Phase Phase 1
Enterome

6 total trials

What the finished NCT04116658 record still lists

NCT04116658 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% higher).

The record links to 0 conditions, and to 1 intervention - of which Multiple dose of EO2401 is the first listed.

NCT04116658 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04116658 about?

NCT04116658 is a clinical study titled "First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma". The purpose of this study is to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in patients with unequivocal evidence of progressive or first recurrent glioblastoma.

What is the current status of trial NCT04116658?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2020-07-13. Estimated completion is 2024-03-04.

What interventions are being tested in trial NCT04116658?

The interventions under investigation include: Multiple dose of EO2401 (BIOLOGICAL).

Who is sponsoring clinical trial NCT04116658?

This trial is sponsored by Enterome, which has 6 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04116658's enrollment target sits among peer trials

100 546th of 2000 higher than 1,411 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04116658, the US trial registry maintained by the National Library of Medicine. NCT04116658 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.